Front Page News

Biogen Receives FDA Approval of High Dose SPINRAZA for the Treatment of SMA

March 30, 2026
Posted in , ,

Biogen today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the High Dose regimen of SPINRAZA (nusinersen) to […]

Cure SMA Awards $150,000 Grant to Tetsuya Akiyama, MD, PhD, Stanford University School of Medicine

March 20, 2026
Posted in , , ,

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal […]

Cure SMA Expands Travel Support Package Eligibility to Include Teens with SMA

March 20, 2026
Posted in , ,

Cure SMA is excited to share an important update to our travel support programs. In response to community feedback and the growing need for accessible […]

Genentech Issues Community Letter Regarding Emugrobart

March 19, 2026
Posted in , ,

Today, Genentech announced the discontinuation of emugrobart (an investigational anti-myostatin antibody, also known as GYM329) into Phase III development for spinal muscular atrophy (SMA). The […]

Cure SMA Awards $75,000 Grant to Lyndsay Murray, PhD, University of Edinburgh in Scotland

March 6, 2026
Posted in , ,

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal […]

Evrysdi Risdiplam Tablet Is Now Approved For Broader Use In SMA

March 6, 2026
Posted in , , ,

We’re excited to share an important update for the spinal muscular atrophy (SMA) community. The U.S. Food and Drug Administration (FDA) has approved a label […]

Cure SMA Awards $150,000 Grant to Christian Simon, PhD, at Leipzig University in Germany

February 25, 2026
Posted in , , ,

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal […]

Novartis Releases Winter SMA Community Update Letter

February 23, 2026
Posted in , ,

Novartis recently shared a Winter 2026 update highlighting the FDA approval of ITVISMA® (onasemnogene abeparvovec-brve) for intrathecal use in people ages 2 and older with […]

Cure SMA Awards $75,000 Grant to Jiangbing Zhou, PhD, at Yale University

February 20, 2026
Posted in , ,

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal […]

Cure SMA Awards $150,000 Grant to Emma Sutton, PhD, at Ottawa Hospital Research Institute in Canada

February 13, 2026
Posted in , , ,

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal […]

Scroll to Top